Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA132 in advanced solid tumors
NCT05478785Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132) in solid tumor, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Incidence of Dose-limiting Toxicities, Incidence of Adverse Events and 4 more. Status: unknown.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05478785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478785.